[
  {
    "ts": "2025-11-18T04:43:10+00:00",
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "93b630e7-811e-35ca-9447-b0ebfd6daa97",
      "content": {
        "id": "93b630e7-811e-35ca-9447-b0ebfd6daa97",
        "contentType": "STORY",
        "title": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
        "description": "",
        "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
        "pubDate": "2025-11-18T04:43:10Z",
        "displayTime": "2025-11-18T04:43:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f",
          "originalWidth": 2400,
          "originalHeight": 1198,
          "caption": "QLYS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tvt.bhG5N6JVrKhmjNYxcA--~B/aD0xMTk4O3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f.cf.webp",
              "width": 2400,
              "height": 1198,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9BTQDaynRaVr6yr6uECGyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "QLYS"
            },
            {
              "symbol": "KBH"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T10:30:00+00:00",
    "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
    "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
    "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
      "content": {
        "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
        "contentType": "STORY",
        "title": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
        "description": "",
        "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
        "pubDate": "2025-11-18T10:30:00Z",
        "displayTime": "2025-11-18T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ac2e96e5-a067-3c02-a2cf-3819f053faab/the-weight-loss-craze-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BONe.IvmYz1PI80IiJvYow--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lZg8ZTfmPAKqUBBdR2wmmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]